An important goal in drug development is to engineer inhibitors and ligands that have high binding affinities for their target molecules. In optimizing these interactions, the precise determination of ...

ALLSCHWIL, SWITZERLAND - 25 June 2015 - Actelion Ltd (ATLN.VX) today announced that data supporting a gradual up-titration dose regimen of ponesimod will be presented at the 12th Congress of the ...

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non–Small-Cell Lung Cancer in a Large Community Oncology Practice Patients receiving taxanes are at risk for ...